128 related articles for article (PubMed ID: 9873675)
1. Orally active indole N-oxide PDE4 inhibitors.
Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
[TBL] [Abstract][Full Text] [Related]
2. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW
Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449
[TBL] [Abstract][Full Text] [Related]
3. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
[TBL] [Abstract][Full Text] [Related]
4. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
[TBL] [Abstract][Full Text] [Related]
5. Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.
Hulme C; Moriarty K; Huang FC; Mason J; McGarry D; Labaudiniere R; Souness J; Djuric S
Bioorg Med Chem Lett; 1998 Feb; 8(4):399-404. PubMed ID: 9871693
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
7. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
[TBL] [Abstract][Full Text] [Related]
9. 8-Methoxyquinolines as PDE4 inhibitors.
Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
Pascal Y; Andrianjara CR; Auclair E; Avenel N; Bertin B; Calvet A; Féru F; Lardon S; Moodley I; Ouagued M; Payne A; Pruniaux MP; Szilagyi C
Bioorg Med Chem Lett; 2000 Jan; 10(1):35-8. PubMed ID: 10636238
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
12. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
[TBL] [Abstract][Full Text] [Related]
14. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Jan; 14(1):29-32. PubMed ID: 14684291
[TBL] [Abstract][Full Text] [Related]
15. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
16. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
17. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide analogs and PDE4 inhibition.
Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
[TBL] [Abstract][Full Text] [Related]
19. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
Regan J; Bruno J; McGarry D; Poli G; Hanney B; Bower S; Travis J; Sweeney D; Miller B; Souness J; Djuric S
Bioorg Med Chem Lett; 1998 Oct; 8(19):2737-42. PubMed ID: 9873613
[TBL] [Abstract][Full Text] [Related]
20. Aryl sulfonamides as selective PDE4 inhibitors.
Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
